Data gathered: November 14
Alternative Data for Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
| Price | $152.95 |
| Target Price | Sign up |
| Volume | 3,510,000 |
| Market Cap | $373B |
| Year Range | $142.19 - $167.38 |
| Dividend Yield | 3.2% |
| PE Ratio | 25.65 |
| Analyst Rating | 38% buy |
| Industry | Drug Manufacturers |
In the news
 |
Johnson & Johnson sues Biden administration over payment terms for 340B hospitalsNovember 13 - Biztoc.com |
 |
Greece as a center of innovation: Johnson & Johnson Innovative Medicine’s strategy for new treatments and clinical studiesNovember 13 - Naftemporiki.gr |
 |
Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive IncomeNovember 13 - Yahoo |
Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical SystemNovember 12 - Finnhub |
|
 |
Johnson & Johnson: Tracking Well Above The IndustryNovember 12 - SeekingAlpha |
Johnson & Johnson - Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjogren's diseaseNovember 11 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 22.5B | 13.7B | 15.5B | 2.69B | 5.04B | 2.420 |
| Q2 '24 | 22.4B | 13.6B | 15.6B | 4.69B | 6.47B | 2.820 |
| Q1 '24 | 21.2B | 13.2B | 14.9B | 3.26B | 4.97B | 2.710 |
| Q4 '23 | 21.4B | 14.1B | 14.6B | 4.05B | 5.99B | 2.290 |
| Q3 '23 | 21.2B | 13.3B | 14.7B | 26B | 28.2B | 2.660 |
Insider Transactions View All
| Decker Robert J filed to sell 18,973 shares at $165.1. September 3 '24 |
| Broadhurst Vanessa filed to sell 15,043 shares at $162.2. March 13 '24 |
| Taubert Jennifer L filed to sell 141,416 shares at $156.3. February 12 '24 |
| Hait William filed to sell 87,747 shares at $172. July 27 '23 |
| Fasolo Peter filed to sell 102,696 shares at $170.3. July 27 '23 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Eli Lilly and CompanyLLY |
$798.32 1.7% | 67 |
 |
PfizerPFE |
$26.51 0.8% | 51 |
 |
AstrazenecaAZN |
$65.91 0.9% | 73 |
 |
AbbVieABBV |
$171.1 0.4% | 57 |
 |
TherapeuticsMDTXMD |
$1.48 1.3% | 37 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Lloyd Doggett |
Oct 10, 24 | Buy | $1K - $15K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
| C. Scott Franklin |
Aug 20, 24 | Buy | $15K - $50K |
Read more about Johnson & Johnson (JNJ) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Johnson & Johnson?
The Market Cap of Johnson & Johnson is $373B.
What is Johnson & Johnson's PE Ratio?
As of today, Johnson & Johnson's PE (Price to Earnings) ratio is 25.65.
What is the current stock price of Johnson & Johnson?
Currently, the price of one share of Johnson & Johnson stock is $152.95.
How can I analyze the JNJ stock price chart for investment decisions?
The JNJ stock price chart above provides a comprehensive visual representation of Johnson & Johnson's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Johnson & Johnson shares. Our platform offers an up-to-date JNJ stock price chart, along with technical data analysis and alternative data insights.
Does JNJ offer dividends to its shareholders?
Yes, Johnson & Johnson (JNJ) offers dividends to its shareholders, with a dividend yield of 3.2%. This dividend yield represents Johnson & Johnson's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Johnson & Johnson in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Johnson & Johnson?
Some of the similar stocks of Johnson & Johnson are Eli Lilly and Company, Pfizer, Astrazeneca, AbbVie, and TherapeuticsMD.
.